StocksVertex Pharmaceuticals IncorporatedVRTX


Vertex Pharmaceuticals Incorporated

289.54 -3.26 (-1.11%)
Giá Trì hoãn của NASDAQ, bằng USD Thị trường đóng cửa
Giao dịch
Bài viết đã Ghim
Genome Engineering
Vertex, Verve team up to develop a gene editing drug for liver disease 🔹 $VRTX (Vertex Pharmaceuticals Incorporated) is broadening its reach in gene editing, announcing Wednesday a deal with $VERV (Verve Therapeutics Inc) to develop a one-time treatment for an undisclosed liver disease. Vertex will... Xem thêm Dịch
Bản tin Thị trường
Hàng đầu
Adamos Hadjiantoniou
Đã chỉnh sửa
$VRTX (Vertex Pharmaceuticals Incorporated) and $CRSP (CRISPR Therapeutics AG) announced Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022. “We continue to work with urgency to bring forward the first CRISPR therapy for a genetic disease, and one that holds potential to transform... Xem thêm Dịch
Roland Wen
Đã chỉnh sửa
𝐁𝐢𝐨𝐠𝐞𝐧 𝐒𝐭𝐫𝐢𝐯𝐞𝐬 𝐟𝐨𝐫 𝐓𝐨𝐟𝐞𝐫𝐬𝐞𝐧 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 An in-depth review of pivotal one-year data indicates Biogen’s 𝐭𝐨𝐟𝐞𝐫𝐬𝐞𝐧, being developed for a rare form of 𝐚𝐦𝐲𝐨𝐭𝐫𝐨𝐩𝐡𝐢𝐜 𝐥𝐚𝐭𝐞𝐫𝐚𝐥 𝐬𝐜𝐥𝐞𝐫𝐨𝐬𝐢𝐬 (𝐀𝐋𝐒), slows the decline of the disease through the lowering... Xem thêm Dịch
Thích Bình luậnChia sẻ
$VRTX (Vertex Pharmaceuticals Incorporated) Diversified Trust Co Sells 1,395 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Diversified Trust Co lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 52.3% during the second quarter, according to the company... Xem thêm Dịch
Thích Bình luậnChia sẻ
1 trả lời
Anthony Sofocleous
𝙊𝙐𝙍 𝙇𝙊𝙉𝙂 𝙋𝙊𝙍𝙏𝙁𝙊𝙇𝙄𝙊 𝙊𝙐𝙏𝙇𝙊𝙊𝙆 𝙁𝙊𝙍 𝙉𝙀𝙓𝙏 𝙒𝙀𝙀𝙆 (18.09.2022) (Simple and straight forward analysis) Dear Investors Please find below analysis of our stocks currently existing in our portfolio 𝙊𝙐𝙍 𝙎𝙀𝙋𝙏𝙀𝙈𝘽𝙀𝙍 𝙂𝙊𝘼𝙇 𝙄𝙎 𝟭𝟮% Current Profitability: 𝟲𝟰.𝟭𝟱% Profitable... Xem thêm Dịch